CAP-T
LIVE

Serial Number

79084150

Owner

CEVEC Pharmaceuticals GmbH

Attorney

Jeffrey H. Kamenetsky

Filing Date

May 11, 2010

Add to watchlist:

No watchlists yet
View on USPTO

CAP-T Trademark

Serial Number: 79084150 • Registration: 4036922

CAP-T is a trademark filed by CEVEC Pharmaceuticals GmbH on May 11, 2010. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

CEVEC Pharmaceuticals GmbH (7 trademarks)

Gottfried-Hagen-Strasse 62
51105 Köln , DE

Entity Type: 03

Trademark Details

Filing Date

May 11, 2010

Registration Date

October 11, 2011

Published for Opposition

July 26, 2011

Cancellation Date

May 11, 2020

Goods & Services

Medicines, chemical, biological and biochemical preparations and proteins for the treatment of cancer, tumourous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardiovascular diseases, except thyreostatica and cough and cold medicines; pharmaceutical and veterinary preparations and reagents for use in the treatment of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, except thyreostatica and cough and cold medicines; chemical, biological and biochemical reagents for medical and veterinary purposes, except thyreostatica and cough and cold medicines; diagnostic and analytic preparations for medical and veterinary purposes; cell lines, cells, diagnostic proteins and polypeptides for medical or clinical use; nucleic acid sequences, diagnostic proteins, polypeptides and chemical reagents for medical and veterinary purposes; amino acids for medical or veterinary purposes; diagnostic reagents and preparations, namely, microorganisms, proteins, polypeptides, nucleotides, nucleic acids, cell lines and cells for medical, veterinary and diagnostic purposes, except thyreostatica and cough and cold medicines

Chemical, biological and biochemical additives, preparations and reagents for use in the manufacture of chemicals, biologicals and biochemicals, namely, preparations and reagents for non medical use, in particular for scientific, research, laboratory, industrial and commercial purposes; chemical, biological and biochemical additives, preparations and reagents for research and characterisation of diseases for non-medical purposes; chemical, biological and biochemical additives, preparations and reagents, namely, cell lines, cells, proteins and polypeptides, for scientific and medical research and development of pharmaceuticals; chemical, biological and biochemical additives, preparations and reagents for use in the manufacture of medicines and pharmaceuticals; cultures of microorganisms other than for medical and veterinary use; cell lines, cells and amino acids for laboratory or research use; nucleic acid sequences, proteins and polypaptides for other than medical and veterinary use; diagnostic reagents and preparations comprising proteins, polypeptides, nucleotides, nucleic acids, cell lines and cells for scientific, research, laboratory, and commercial purposes for the development of medicines and for use in the manufacture of medicines and pharmaceuticals

Scientific and industrial research, namely, in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics; research and development of medicines, diagnostic and analytic preparations, methods of therapy and expression systems; scientific and technological consulting services, namely, in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics; industrial consulting services, namely, consultancy pertaining to pharmacology; breeding, recovery, optimisation, synthesis and modification of cell culture lines, cells, microorganisms, polypeptides, proteins, nucleotides, nucleic acids for scientific, research, laboratory, industrial and commercial purposes, namely, for use in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics, for the development of medicines and for use in the manufacture of medicines and pharmaceuticals

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
May 29, 2021 DENC
DEATH OF INTERNATIONAL REGISTRATION
May 29, 2021 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Mar 15, 2019 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jan 28, 2019 INTS
INVALIDATION PROCESSED
Jan 28, 2019 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 18, 2019 INTR
CANCELLED SECTION 71
May 18, 2018 C71T
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 11, 2012 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 21, 2012 FICS
FINAL DISPOSITION PROCESSED
May 21, 2012 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 11, 2012 FICR
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Nov 7, 2011 LIMN
LIMITATION OF GOODS RECEIVED FROM IB
Oct 29, 2011 LIMG
REGISTERED-PRINCIPAL REGISTER
Oct 11, 2011 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 26, 2011 NPUB
PUBLISHED FOR OPPOSITION
Jul 26, 2011 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 20, 2011 PREV
ASSIGNED TO LIE
Jun 16, 2011 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 9, 2011 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 9, 2011 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 9, 2011 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 9, 2011 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 9, 2011 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 7, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 6, 2011 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 6, 2011 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 18, 2011 GNFN
FINAL REFUSAL E-MAILED
Feb 18, 2011 GNFR
FINAL REFUSAL WRITTEN
Feb 18, 2011 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 7, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 7, 2011 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 7, 2011 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 21, 2011 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 21, 2011 REAP
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 5, 2010 CORN
REFUSAL PROCESSED BY IB
Sep 25, 2010 RFNT
CORRECTION TRANSACTION RECEIVED FROM IB
Sep 24, 2010 CRCV
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 30, 2010 RFCS
REFUSAL PROCESSED BY MPU
Aug 30, 2010 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 27, 2010 RFCR
NON-FINAL ACTION WRITTEN
Aug 26, 2010 CNRT
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Aug 25, 2010 CREV
ASSIGNED TO EXAMINER
Aug 24, 2010 DOCK
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Aug 19, 2010 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Aug 19, 2010 CRCV
APPLICATION FILING RECEIPT MAILED
Jul 27, 2010 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 23, 2010 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 22, 2010 REPR